top headlines
ATSN-401, Atsena Therapeutics’ investigational gene therapy for Stargardt disease, has [...]
Quest Diagnostics has integrated its Haystack MRD test and comprehensive [...]
Movers & Shakers
sponsored content
With 89% of AI pilots failing to scale, biopharmas can [...]
Interview with Carol Grassi Mircich, chief commercial marketing and innovation [...]
As Rare Disease Day 2026 highlights the challenges faced by [...]
Other news
Seegene has launched a global clinical study involving one million [...]
Fonseca Biosciences has launched XTORO (finafloxacin otic suspension) 0.3% in [...]
Autolomous and Cellular Origins have integrated their manufacturing platforms to [...]
Evonik is investing US$100 million over the next five years [...]
SGD Pharma has reported a 27% reduction in Scope 1 [...]
Autolomous and Cellular Origins have integrated their platforms to create [...]
